查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
1951910

基因突变分析市场分析及预测（至2035年）：按类型、产品类型、服务、技术、应用、最终用户、组件、部署类型和功能划分

Genetic Mutation Analysis Market Analysis and Forecast to 2035: Type, Product, Services, Technology, Application, End User, Component, Deployment, Functionality
出版日期: | 出版商: Global Insight Services | 英文 331 Pages | 商品交期: 3-5个工作天内

价格
简介目录

基因突变分析市场预计将从2024年的65亿美元成长到2034年的185亿美元，复合年增长率约为11.6%。基因突变分析市场涵盖用于识别和解读基因突变的技术和服务，这些技术和服务对于个人化医疗、诊断和治疗研发至关重要。这些技术和服务包括次世代定序、PCR和生物资讯学工具。遗传疾病的增加和基因组学技术的进步正在推动市场需求，并促进精准医疗和标靶治疗的创新。

基因突变分析市场正经历强劲成长，这主要得益于精准医疗和个人化医疗保健的进步。定序技术领域处于领先地位，其中次世代定序(NGS) 技术凭藉其准确性和成本效益，推动了显着的改进。该领域以全基因测序为主导，它能够提供关于基因突变的全面资讯；其次是靶向定序，它能够对特定目标基因进行重点分析。软体和服务领域也呈现出良好的成长势头，主导生物资讯解决方案尤为突出。这些解决方案对于解读和管理日益增长的基因数据至关重要。虽然基于云端的生物资讯平台因其扩充性和易用性而日益普及，但对于那些优先考虑资料安全和管理的机构而言，本地部署解决方案仍然十分重要。肿瘤学和罕见疾病领域的新兴应用进一步推动了市场扩张，凸显了基因突变分析在医学研究和推进治疗策略方面的重要性。

市场区隔
类型 单核苷酸多态性（SNP）分析、拷贝数变异（CNV）分析、大规模突变分析
产品 试剂/试剂盒、设备、软体、耗材
服务 基因检测服务、数据解读服务、咨询服务
科技 次世代定序(NGS)、聚合酵素链锁反应(PCR)、微阵列、桑格定序、CRISPR
应用领域 肿瘤学、心血管疾病、神经系统疾病、感染疾病、遗传性疾病、药物遗传学
最终用户 医院和诊所、研究机构、製药和生物技术公司、诊断检查室
成分 硬体、软体和服务
实施表格 基于云端的，本地部署的
功能 数据分析、数据管理、数据视觉化

基因突变分析市场呈现市场份额动态分布的特点，主要参与者不断透过新产品推出进行创新。定价策略竞争激烈，受到技术进步和精准医疗需求的影响。该领域正经历新型诊断工具的快速成长，这些工具提高了突变检测的准确性，促进了其在医疗保健系统中的应用。各公司正致力于建立策略联盟，以扩展其产品系列併应对更广泛的遗传疾病。随着遗传疾病的增加，对先进突变分析解决方案的需求日益增长，市场正以惊人的速度发展。竞争基准分析表明，少数主要企业正在引领市场，并透过持续创新和策略联盟来制定行业标准。监管的影响也十分显着，严格的指导方针规范着产品开发和市场准入。北美在监管合规方面处于领先领先，而亚太地区由于政府的积极倡议，已成为主要市场参与者。竞争环境十分激烈，各公司都在加大研发投入以维持其技术优势。法规环境既带来挑战也带来机会，在促进创新的同时，也确保了病人安全和基因检测的有效性。

主要趋势和驱动因素：

在基因组技术和个人化医疗的推动下，基因突变分析市场持续稳定成长。一个显着的趋势是，市场对精准诊断的需求日益增长，精准诊断能够根据每个人的基因谱制定更精准的治疗方案。这项转变源自于遗传性疾病和癌症发生率的不断上升，凸显了早期准确检测方法的重要性。此外，人工智慧 (AI) 和机器学习在基因分析中的应用，提升了资料解读和预测能力。这些技术简化了工作流程，并提高了突变检测的准确性。另一个关键驱动因素是公共和私营部门不断增加的研发投入，旨在发现新的基因见解和治疗标靶。消费者基因检测服务的扩展也是一个显着的趋势，它使人们能够更便捷地获取基因讯息，并为个人提供个人化的健康资讯。新兴市场拥有不断完善的医疗基础设施和日益普及的基因检测，蕴藏着许多机会。随着全球对遗传健康风险的认识不断提高，提供创新且经济高效解决方案的公司有望占据可观的市场份额。

目录

第一章执行摘要

第二章 市集亮点

第三章 市场动态

  • 宏观经济分析
  • 市场趋势
  • 市场驱动因素
  • 市场机会
  • 市场限制
  • 复合年均成长率：成长分析
  • 影响分析
  • 新兴市场
  • 技术蓝图
  • 战略框架

第四章 细分市场分析

  • 市场规模及预测：依类型
    • 单核苷酸多态性（SNP）分析
    • 拷贝数变异（CNV）分析
    • 大规模突变分析
  • 市场规模及预测：依产品划分
    • 试剂和试剂盒
    • 分析器
    • 软体
    • 消耗品
  • 市场规模及预测：依服务划分
    • 基因检测服务
    • 数据解读服务
    • 咨询服务
  • 市场规模及预测：依技术划分
    • 次世代定序（NGS）
    • 聚合酵素链锁反应（PCR）
    • 微阵列
    • 桑格定序
    • CRISPR
  • 市场规模及预测：依应用领域划分
    • 肿瘤学
    • 心血管疾病
    • 神经系统疾病
    • 感染疾病
    • 遗传性疾病
    • 药物基因体学
  • 市场规模及预测：依最终用户划分
    • 医院和诊所
    • 研究所
    • 製药和生物技术公司
    • 诊断检查室
  • 市场规模及预测：依组件划分
    • 硬体
    • 软体
    • 服务
  • 市场规模及预测：依发展状况
    • 基于云端的
    • 本地部署
  • 市场规模及预测：依功能划分
    • 数据分析
    • 资料管理
    • 数据视觉化

第五章 区域分析

  • 北美洲
    • 我们
    • 加拿大
    • 墨西哥
  • 拉丁美洲
    • 巴西
    • 阿根廷
    • 其他拉丁美洲地区
  • 亚太地区
    • 中国
    • 印度
    • 韩国
    • 日本
    • 澳洲
    • 台湾
    • 亚太其他地区
  • 欧洲
    • 德国
    • 法国
    • 英国
    • 西班牙
    • 义大利
    • 其他欧洲地区
  • 中东和非洲
    • 沙乌地阿拉伯
    • 阿拉伯聯合大公国
    • 南非
    • 撒哈拉以南非洲
    • 其他中东和非洲地区

第六章 市场策略

  • 需求与供给差距分析
  • 贸易和物流限制
  • 价格、成本和利润率趋势
  • 市场渗透率
  • 消费者分析
  • 法规概述

第七章 竞争讯息

  • 市场定位
  • 市场占有率
  • 竞争基准
  • 主要企业的策略

第八章 公司简介

  • Illumina
  • Thermo Fisher Scientific
  • Qiagen
  • Bio-Rad Laboratories
  • Agilent Technologies
  • Roche Diagnostics
  • Perkin Elmer
  • Pacific Biosciences
  • Oxford Nanopore Technologies
  • BGI Genomics
  • Genewiz
  • Genscript Biotech
  • LGC Biosearch Technologies
  • Takara Bio
  • Fluidigm Corporation
  • 10x Genomics
  • Personalis
  • Myriad Genetics
  • Genomic Health
  • Natera

第九章：关于我们

简介目录
Product Code: GIS10968

Genetic Mutation Analysis Market is anticipated to expand from $6.5 billion in 2024 to $18.5 billion by 2034, growing at a CAGR of approximately 11.6%. The Genetic Mutation Analysis Market encompasses technologies and services that identify and interpret genetic mutations, crucial for personalized medicine, diagnostics, and therapeutic development. This market includes next-generation sequencing, PCR, and bioinformatics tools. The rising incidence of genetic disorders and advancements in genomics propel demand, fostering innovation in precision medicine and targeted therapies.

The Genetic Mutation Analysis Market is experiencing robust growth, propelled by advancements in precision medicine and personalized healthcare. The sequencing technology segment is at the forefront, with next-generation sequencing (NGS) technologies driving significant performance due to their accuracy and cost-effectiveness. Within this segment, whole-genome sequencing outpaces others, offering comprehensive insights into genetic variations. Targeted sequencing follows closely, providing focused analysis on specific genes of interest. The software and services segment also shows promising growth, with bioinformatics solutions leading the way. These solutions are essential for data interpretation and management, supporting the increasing volume of genetic data. Cloud-based bioinformatics platforms are gaining popularity due to their scalability and accessibility, while on-premise solutions remain vital for institutions prioritizing data security and control. Emerging applications in oncology and rare diseases further fuel market expansion, highlighting the importance of genetic mutation analysis in advancing medical research and treatment strategies.

Market Segmentation
TypeSingle Nucleotide Polymorphism (SNP) Analysis, Copy Number Variation (CNV) Analysis, Large-Scale Mutation Analysis
ProductReagents and Kits, Instruments, Software, Consumables
ServicesGenetic Testing Services, Data Interpretation Services, Consultation Services
TechnologyNext-Generation Sequencing (NGS), Polymerase Chain Reaction (PCR), Microarray, Sanger Sequencing, CRISPR
ApplicationOncology, Cardiovascular Diseases, Neurological Disorders, Infectious Diseases, Genetic Disorders, Pharmacogenomics
End UserHospitals and Clinics, Research Institutes, Pharmaceutical and Biotechnology Companies, Diagnostic Laboratories
ComponentHardware, Software, Services
DeploymentCloud-Based, On-Premise
FunctionalityData Analysis, Data Management, Data Visualization

The Genetic Mutation Analysis Market is characterized by a dynamic distribution of market share, with key players consistently innovating through new product launches. Pricing strategies remain competitive, influenced by technological advancements and the demand for precision medicine. The sector is witnessing a surge in novel diagnostic tools that enhance mutation detection accuracy, driving adoption across healthcare systems. Companies are focusing on strategic collaborations to expand their product portfolios, thereby catering to a broader spectrum of genetic disorders. The market's evolution is propelled by the increasing prevalence of genetic diseases, necessitating advanced mutation analysis solutions. In terms of competition benchmarking, the market is dominated by a few major players who set industry standards through continuous innovation and strategic partnerships. Regulatory influences are significant, with stringent guidelines shaping product development and market entry. North America leads in regulatory compliance, while Asia-Pacific is emerging as a key player due to favorable government initiatives. The landscape is competitive, with companies investing in R&D to maintain a technological edge. The regulatory environment is both a challenge and an opportunity, fostering innovation while ensuring patient safety and efficacy in genetic testing.

Geographical Overview:

The genetic mutation analysis market is witnessing robust growth across various regions, each exhibiting unique dynamics. North America leads the market, propelled by advanced healthcare infrastructure and substantial investments in genomic research. The region's strong focus on precision medicine and personalized healthcare further fuels market expansion. Europe follows, with significant investments in genomic technologies and a well-established regulatory framework supporting market growth. The region's emphasis on healthcare innovation and research excellence enhances its competitive edge. In Asia Pacific, the market is expanding rapidly, driven by increasing healthcare expenditures and technological advancements in genomics. Emerging economies such as China and India are at the forefront, investing heavily in genomic research and infrastructure. Latin America and the Middle East & Africa are emerging growth pockets. Latin America is experiencing a surge in healthcare investments, while the Middle East & Africa are recognizing the potential of genetic mutation analysis in advancing healthcare outcomes and innovation.

Global tariffs and geopolitical tensions are significantly influencing the Genetic Mutation Analysis Market, particularly in East Asia. Japan and South Korea are experiencing increased costs due to tariffs on imported genetic sequencing equipment, prompting a shift towards enhancing domestic R&D capabilities. China is accelerating its efforts to develop indigenous biotechnologies in response to export restrictions, while Taiwan remains a pivotal player in biotech manufacturing but faces geopolitical vulnerabilities. The global market for genetic analysis is expanding robustly, driven by advancements in personalized medicine and genomics. By 2035, the market is expected to flourish with a focus on regional collaborations and technological innovation. Middle East conflicts, while primarily affecting energy prices, indirectly impact the cost structure of biotech supply chains, necessitating strategic resilience planning.

Key Trends and Drivers:

The Genetic Mutation Analysis Market is experiencing robust expansion, fueled by advancements in genomic technologies and personalized medicine. A significant trend is the growing demand for precision diagnostics, enabling more accurate treatment plans tailored to individual genetic profiles. This shift is driven by the increasing prevalence of genetic disorders and cancer, underscoring the necessity for early and precise detection methods. Moreover, the integration of artificial intelligence and machine learning in genetic analysis is enhancing data interpretation and predictive capabilities. These technologies are streamlining workflows and improving the accuracy of mutation detection. Another pivotal driver is the rising investment in research and development by both public and private sectors, aiming to uncover novel genetic insights and therapeutic targets. The expansion of direct-to-consumer genetic testing services is also a notable trend, democratizing access to genetic information and empowering individuals with personalized health insights. Opportunities abound in emerging markets where healthcare infrastructure is evolving, and genetic testing adoption is on the rise. Companies that offer innovative, cost-effective solutions are poised to capture significant market share, particularly as awareness of genetic health implications grows globally.

Research Scope:

  • Estimates and forecasts the overall market size across type, application, and region.
  • Provides detailed information and key takeaways on qualitative and quantitative trends, dynamics, business framework, competitive landscape, and company profiling.
  • Identifies factors influencing market growth and challenges, opportunities, drivers, and restraints.
  • Identifies factors that could limit company participation in international markets to help calibrate market share expectations and growth rates.
  • Evaluates key development strategies like acquisitions, product launches, mergers, collaborations, business expansions, agreements, partnerships, and R&D activities.
  • Analyzes smaller market segments strategically, focusing on their potential, growth patterns, and impact on the overall market.
  • Outlines the competitive landscape, assessing business and corporate strategies to monitor and dissect competitive advancements.

Our research scope provides comprehensive market data, insights, and analysis across a variety of critical areas. We cover Local Market Analysis, assessing consumer demographics, purchasing behaviors, and market size within specific regions to identify growth opportunities. Our Local Competition Review offers a detailed evaluation of competitors, including their strengths, weaknesses, and market positioning. We also conduct Local Regulatory Reviews to ensure businesses comply with relevant laws and regulations. Industry Analysis provides an in-depth look at market dynamics, key players, and trends. Additionally, we offer Cross-Segmental Analysis to identify synergies between different market segments, as well as Production-Consumption and Demand-Supply Analysis to optimize supply chain efficiency. Our Import-Export Analysis helps businesses navigate global trade environments by evaluating trade flows and policies. These insights empower clients to make informed strategic decisions, mitigate risks, and capitalize on market opportunities.

TABLE OF CONTENTS

1 Executive Summary

  • 1.1 Market Size and Forecast
  • 1.2 Market Overview
  • 1.3 Market Snapshot
  • 1.4 Regional Snapshot
  • 1.5 Strategic Recommendations
  • 1.6 Analyst Notes

2 Market Highlights

  • 2.1 Key Market Highlights by Type
  • 2.2 Key Market Highlights by Product
  • 2.3 Key Market Highlights by Services
  • 2.4 Key Market Highlights by Technology
  • 2.5 Key Market Highlights by Application
  • 2.6 Key Market Highlights by End User
  • 2.7 Key Market Highlights by Component
  • 2.8 Key Market Highlights by Deployment
  • 2.9 Key Market Highlights by Functionality

3 Market Dynamics

  • 3.1 Macroeconomic Analysis
  • 3.2 Market Trends
  • 3.3 Market Drivers
  • 3.4 Market Opportunities
  • 3.5 Market Restraints
  • 3.6 CAGR Growth Analysis
  • 3.7 Impact Analysis
  • 3.8 Emerging Markets
  • 3.9 Technology Roadmap
  • 3.10 Strategic Frameworks
    • 3.10.1 PORTER's 5 Forces Model
    • 3.10.2 ANSOFF Matrix
    • 3.10.3 4P's Model
    • 3.10.4 PESTEL Analysis

4 Segment Analysis

  • 4.1 Market Size & Forecast by Type (2020-2035)
    • 4.1.1 Single Nucleotide Polymorphism (SNP) Analysis
    • 4.1.2 Copy Number Variation (CNV) Analysis
    • 4.1.3 Large-Scale Mutation Analysis
  • 4.2 Market Size & Forecast by Product (2020-2035)
    • 4.2.1 Reagents and Kits
    • 4.2.2 Instruments
    • 4.2.3 Software
    • 4.2.4 Consumables
  • 4.3 Market Size & Forecast by Services (2020-2035)
    • 4.3.1 Genetic Testing Services
    • 4.3.2 Data Interpretation Services
    • 4.3.3 Consultation Services
  • 4.4 Market Size & Forecast by Technology (2020-2035)
    • 4.4.1 Next-Generation Sequencing (NGS)
    • 4.4.2 Polymerase Chain Reaction (PCR)
    • 4.4.3 Microarray
    • 4.4.4 Sanger Sequencing
    • 4.4.5 CRISPR
  • 4.5 Market Size & Forecast by Application (2020-2035)
    • 4.5.1 Oncology
    • 4.5.2 Cardiovascular Diseases
    • 4.5.3 Neurological Disorders
    • 4.5.4 Infectious Diseases
    • 4.5.5 Genetic Disorders
    • 4.5.6 Pharmacogenomics
  • 4.6 Market Size & Forecast by End User (2020-2035)
    • 4.6.1 Hospitals and Clinics
    • 4.6.2 Research Institutes
    • 4.6.3 Pharmaceutical and Biotechnology Companies
    • 4.6.4 Diagnostic Laboratories
  • 4.7 Market Size & Forecast by Component (2020-2035)
    • 4.7.1 Hardware
    • 4.7.2 Software
    • 4.7.3 Services
  • 4.8 Market Size & Forecast by Deployment (2020-2035)
    • 4.8.1 Cloud-Based
    • 4.8.2 On-Premise
  • 4.9 Market Size & Forecast by Functionality (2020-2035)
    • 4.9.1 Data Analysis
    • 4.9.2 Data Management
    • 4.9.3 Data Visualization

5 Regional Analysis

  • 5.1 Global Market Overview
  • 5.2 North America Market Size (2020-2035)
    • 5.2.1 United States
      • 5.2.1.1 Type
      • 5.2.1.2 Product
      • 5.2.1.3 Services
      • 5.2.1.4 Technology
      • 5.2.1.5 Application
      • 5.2.1.6 End User
      • 5.2.1.7 Component
      • 5.2.1.8 Deployment
      • 5.2.1.9 Functionality
    • 5.2.2 Canada
      • 5.2.2.1 Type
      • 5.2.2.2 Product
      • 5.2.2.3 Services
      • 5.2.2.4 Technology
      • 5.2.2.5 Application
      • 5.2.2.6 End User
      • 5.2.2.7 Component
      • 5.2.2.8 Deployment
      • 5.2.2.9 Functionality
    • 5.2.3 Mexico
      • 5.2.3.1 Type
      • 5.2.3.2 Product
      • 5.2.3.3 Services
      • 5.2.3.4 Technology
      • 5.2.3.5 Application
      • 5.2.3.6 End User
      • 5.2.3.7 Component
      • 5.2.3.8 Deployment
      • 5.2.3.9 Functionality
  • 5.3 Latin America Market Size (2020-2035)
    • 5.3.1 Brazil
      • 5.3.1.1 Type
      • 5.3.1.2 Product
      • 5.3.1.3 Services
      • 5.3.1.4 Technology
      • 5.3.1.5 Application
      • 5.3.1.6 End User
      • 5.3.1.7 Component
      • 5.3.1.8 Deployment
      • 5.3.1.9 Functionality
    • 5.3.2 Argentina
      • 5.3.2.1 Type
      • 5.3.2.2 Product
      • 5.3.2.3 Services
      • 5.3.2.4 Technology
      • 5.3.2.5 Application
      • 5.3.2.6 End User
      • 5.3.2.7 Component
      • 5.3.2.8 Deployment
      • 5.3.2.9 Functionality
    • 5.3.3 Rest of Latin America
      • 5.3.3.1 Type
      • 5.3.3.2 Product
      • 5.3.3.3 Services
      • 5.3.3.4 Technology
      • 5.3.3.5 Application
      • 5.3.3.6 End User
      • 5.3.3.7 Component
      • 5.3.3.8 Deployment
      • 5.3.3.9 Functionality
  • 5.4 Asia-Pacific Market Size (2020-2035)
    • 5.4.1 China
      • 5.4.1.1 Type
      • 5.4.1.2 Product
      • 5.4.1.3 Services
      • 5.4.1.4 Technology
      • 5.4.1.5 Application
      • 5.4.1.6 End User
      • 5.4.1.7 Component
      • 5.4.1.8 Deployment
      • 5.4.1.9 Functionality
    • 5.4.2 India
      • 5.4.2.1 Type
      • 5.4.2.2 Product
      • 5.4.2.3 Services
      • 5.4.2.4 Technology
      • 5.4.2.5 Application
      • 5.4.2.6 End User
      • 5.4.2.7 Component
      • 5.4.2.8 Deployment
      • 5.4.2.9 Functionality
    • 5.4.3 South Korea
      • 5.4.3.1 Type
      • 5.4.3.2 Product
      • 5.4.3.3 Services
      • 5.4.3.4 Technology
      • 5.4.3.5 Application
      • 5.4.3.6 End User
      • 5.4.3.7 Component
      • 5.4.3.8 Deployment
      • 5.4.3.9 Functionality
    • 5.4.4 Japan
      • 5.4.4.1 Type
      • 5.4.4.2 Product
      • 5.4.4.3 Services
      • 5.4.4.4 Technology
      • 5.4.4.5 Application
      • 5.4.4.6 End User
      • 5.4.4.7 Component
      • 5.4.4.8 Deployment
      • 5.4.4.9 Functionality
    • 5.4.5 Australia
      • 5.4.5.1 Type
      • 5.4.5.2 Product
      • 5.4.5.3 Services
      • 5.4.5.4 Technology
      • 5.4.5.5 Application
      • 5.4.5.6 End User
      • 5.4.5.7 Component
      • 5.4.5.8 Deployment
      • 5.4.5.9 Functionality
    • 5.4.6 Taiwan
      • 5.4.6.1 Type
      • 5.4.6.2 Product
      • 5.4.6.3 Services
      • 5.4.6.4 Technology
      • 5.4.6.5 Application
      • 5.4.6.6 End User
      • 5.4.6.7 Component
      • 5.4.6.8 Deployment
      • 5.4.6.9 Functionality
    • 5.4.7 Rest of APAC
      • 5.4.7.1 Type
      • 5.4.7.2 Product
      • 5.4.7.3 Services
      • 5.4.7.4 Technology
      • 5.4.7.5 Application
      • 5.4.7.6 End User
      • 5.4.7.7 Component
      • 5.4.7.8 Deployment
      • 5.4.7.9 Functionality
  • 5.5 Europe Market Size (2020-2035)
    • 5.5.1 Germany
      • 5.5.1.1 Type
      • 5.5.1.2 Product
      • 5.5.1.3 Services
      • 5.5.1.4 Technology
      • 5.5.1.5 Application
      • 5.5.1.6 End User
      • 5.5.1.7 Component
      • 5.5.1.8 Deployment
      • 5.5.1.9 Functionality
    • 5.5.2 France
      • 5.5.2.1 Type
      • 5.5.2.2 Product
      • 5.5.2.3 Services
      • 5.5.2.4 Technology
      • 5.5.2.5 Application
      • 5.5.2.6 End User
      • 5.5.2.7 Component
      • 5.5.2.8 Deployment
      • 5.5.2.9 Functionality
    • 5.5.3 United Kingdom
      • 5.5.3.1 Type
      • 5.5.3.2 Product
      • 5.5.3.3 Services
      • 5.5.3.4 Technology
      • 5.5.3.5 Application
      • 5.5.3.6 End User
      • 5.5.3.7 Component
      • 5.5.3.8 Deployment
      • 5.5.3.9 Functionality
    • 5.5.4 Spain
      • 5.5.4.1 Type
      • 5.5.4.2 Product
      • 5.5.4.3 Services
      • 5.5.4.4 Technology
      • 5.5.4.5 Application
      • 5.5.4.6 End User
      • 5.5.4.7 Component
      • 5.5.4.8 Deployment
      • 5.5.4.9 Functionality
    • 5.5.5 Italy
      • 5.5.5.1 Type
      • 5.5.5.2 Product
      • 5.5.5.3 Services
      • 5.5.5.4 Technology
      • 5.5.5.5 Application
      • 5.5.5.6 End User
      • 5.5.5.7 Component
      • 5.5.5.8 Deployment
      • 5.5.5.9 Functionality
    • 5.5.6 Rest of Europe
      • 5.5.6.1 Type
      • 5.5.6.2 Product
      • 5.5.6.3 Services
      • 5.5.6.4 Technology
      • 5.5.6.5 Application
      • 5.5.6.6 End User
      • 5.5.6.7 Component
      • 5.5.6.8 Deployment
      • 5.5.6.9 Functionality
  • 5.6 Middle East & Africa Market Size (2020-2035)
    • 5.6.1 Saudi Arabia
      • 5.6.1.1 Type
      • 5.6.1.2 Product
      • 5.6.1.3 Services
      • 5.6.1.4 Technology
      • 5.6.1.5 Application
      • 5.6.1.6 End User
      • 5.6.1.7 Component
      • 5.6.1.8 Deployment
      • 5.6.1.9 Functionality
    • 5.6.2 United Arab Emirates
      • 5.6.2.1 Type
      • 5.6.2.2 Product
      • 5.6.2.3 Services
      • 5.6.2.4 Technology
      • 5.6.2.5 Application
      • 5.6.2.6 End User
      • 5.6.2.7 Component
      • 5.6.2.8 Deployment
      • 5.6.2.9 Functionality
    • 5.6.3 South Africa
      • 5.6.3.1 Type
      • 5.6.3.2 Product
      • 5.6.3.3 Services
      • 5.6.3.4 Technology
      • 5.6.3.5 Application
      • 5.6.3.6 End User
      • 5.6.3.7 Component
      • 5.6.3.8 Deployment
      • 5.6.3.9 Functionality
    • 5.6.4 Sub-Saharan Africa
      • 5.6.4.1 Type
      • 5.6.4.2 Product
      • 5.6.4.3 Services
      • 5.6.4.4 Technology
      • 5.6.4.5 Application
      • 5.6.4.6 End User
      • 5.6.4.7 Component
      • 5.6.4.8 Deployment
      • 5.6.4.9 Functionality
    • 5.6.5 Rest of MEA
      • 5.6.5.1 Type
      • 5.6.5.2 Product
      • 5.6.5.3 Services
      • 5.6.5.4 Technology
      • 5.6.5.5 Application
      • 5.6.5.6 End User
      • 5.6.5.7 Component
      • 5.6.5.8 Deployment
      • 5.6.5.9 Functionality

6 Market Strategy

  • 6.1 Demand-Supply Gap Analysis
  • 6.2 Trade & Logistics Constraints
  • 6.3 Price-Cost-Margin Trends
  • 6.4 Market Penetration
  • 6.5 Consumer Analysis
  • 6.6 Regulatory Snapshot

7 Competitive Intelligence

  • 7.1 Market Positioning
  • 7.2 Market Share
  • 7.3 Competition Benchmarking
  • 7.4 Top Company Strategies

8 Company Profiles

  • 8.1 Illumina
    • 8.1.1 Overview
    • 8.1.2 Product Summary
    • 8.1.3 Financial Performance
    • 8.1.4 SWOT Analysis
  • 8.2 Thermo Fisher Scientific
    • 8.2.1 Overview
    • 8.2.2 Product Summary
    • 8.2.3 Financial Performance
    • 8.2.4 SWOT Analysis
  • 8.3 Qiagen
    • 8.3.1 Overview
    • 8.3.2 Product Summary
    • 8.3.3 Financial Performance
    • 8.3.4 SWOT Analysis
  • 8.4 Bio-Rad Laboratories
    • 8.4.1 Overview
    • 8.4.2 Product Summary
    • 8.4.3 Financial Performance
    • 8.4.4 SWOT Analysis
  • 8.5 Agilent Technologies
    • 8.5.1 Overview
    • 8.5.2 Product Summary
    • 8.5.3 Financial Performance
    • 8.5.4 SWOT Analysis
  • 8.6 Roche Diagnostics
    • 8.6.1 Overview
    • 8.6.2 Product Summary
    • 8.6.3 Financial Performance
    • 8.6.4 SWOT Analysis
  • 8.7 Perkin Elmer
    • 8.7.1 Overview
    • 8.7.2 Product Summary
    • 8.7.3 Financial Performance
    • 8.7.4 SWOT Analysis
  • 8.8 Pacific Biosciences
    • 8.8.1 Overview
    • 8.8.2 Product Summary
    • 8.8.3 Financial Performance
    • 8.8.4 SWOT Analysis
  • 8.9 Oxford Nanopore Technologies
    • 8.9.1 Overview
    • 8.9.2 Product Summary
    • 8.9.3 Financial Performance
    • 8.9.4 SWOT Analysis
  • 8.10 BGI Genomics
    • 8.10.1 Overview
    • 8.10.2 Product Summary
    • 8.10.3 Financial Performance
    • 8.10.4 SWOT Analysis
  • 8.11 Genewiz
    • 8.11.1 Overview
    • 8.11.2 Product Summary
    • 8.11.3 Financial Performance
    • 8.11.4 SWOT Analysis
  • 8.12 Genscript Biotech
    • 8.12.1 Overview
    • 8.12.2 Product Summary
    • 8.12.3 Financial Performance
    • 8.12.4 SWOT Analysis
  • 8.13 LGC Biosearch Technologies
    • 8.13.1 Overview
    • 8.13.2 Product Summary
    • 8.13.3 Financial Performance
    • 8.13.4 SWOT Analysis
  • 8.14 Takara Bio
    • 8.14.1 Overview
    • 8.14.2 Product Summary
    • 8.14.3 Financial Performance
    • 8.14.4 SWOT Analysis
  • 8.15 Fluidigm Corporation
    • 8.15.1 Overview
    • 8.15.2 Product Summary
    • 8.15.3 Financial Performance
    • 8.15.4 SWOT Analysis
  • 8.16 10x Genomics
    • 8.16.1 Overview
    • 8.16.2 Product Summary
    • 8.16.3 Financial Performance
    • 8.16.4 SWOT Analysis
  • 8.17 Personalis
    • 8.17.1 Overview
    • 8.17.2 Product Summary
    • 8.17.3 Financial Performance
    • 8.17.4 SWOT Analysis
  • 8.18 Myriad Genetics
    • 8.18.1 Overview
    • 8.18.2 Product Summary
    • 8.18.3 Financial Performance
    • 8.18.4 SWOT Analysis
  • 8.19 Genomic Health
    • 8.19.1 Overview
    • 8.19.2 Product Summary
    • 8.19.3 Financial Performance
    • 8.19.4 SWOT Analysis
  • 8.20 Natera
    • 8.20.1 Overview
    • 8.20.2 Product Summary
    • 8.20.3 Financial Performance
    • 8.20.4 SWOT Analysis

9 About Us

  • 9.1 About Us
  • 9.2 Research Methodology
  • 9.3 Research Workflow
  • 9.4 Consulting Services
  • 9.5 Our Clients
  • 9.6 Client Testimonials
  • 9.7 Contact Us